Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Alzheimer's drugs
Biotech
Eisai rocked by 2nd death ahead of Alzheimer’s data reveal
A neuropathologist said "there’s zero doubt in my mind that this is a treatment-caused illness and death."
Nick Paul Taylor
Nov 28, 2022 10:53am
TauRx plans Alzheimer's approval filing despite phase 3 failings
Oct 6, 2022 8:00am
In 'major surprise,' Eisai, Biogen post pivotal Alzheimer's win
Sep 28, 2022 4:30am
Alzheon's Alzheimer's asset axes brain injury biomarker in trial
Sep 20, 2022 6:55am
BioVie gets stock bump on small, midphase Alzheimer's data drop
Sep 7, 2022 8:20am
Vivoryon's stock climbs on midphase Alzheimer's disease data
Aug 1, 2022 6:00am
